Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -33.11% | -51.29% | -46.60% | -38.28% | -30.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.11% | -51.29% | -46.60% | -38.28% | -30.91% |
| Cost of Revenue | -41.29% | -46.16% | -48.26% | -51.97% | -42.90% |
| Gross Profit | -31.58% | -52.19% | -46.26% | -34.93% | -28.08% |
| SG&A Expenses | -16.17% | -18.57% | -24.98% | -31.49% | -32.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.91% | -22.44% | -34.05% | -39.45% | -38.94% |
| Operating Income | 22.44% | 1.02% | 26.60% | 40.00% | 42.18% |
| Income Before Tax | 19.48% | 4.40% | 38.83% | 46.77% | 51.21% |
| Income Tax Expenses | -66.86% | 33.63% | -138.15% | -74.74% | -47.44% |
| Earnings from Continuing Operations | 19.62% | 4.31% | 38.99% | 46.88% | 51.26% |
| Earnings from Discontinued Operations | 118.43% | 77.51% | -175.08% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.07% | 7.74% | 35.52% | 42.83% | 47.86% |
| EBIT | 22.44% | 1.02% | 26.60% | 40.00% | 42.18% |
| EBITDA | 22.78% | 0.69% | 27.86% | 43.02% | 45.23% |
| EPS Basic | 32.63% | 14.50% | 40.42% | 46.85% | 51.74% |
| Normalized Basic EPS | 27.71% | 2.58% | 29.78% | 43.48% | 44.90% |
| EPS Diluted | 32.56% | 14.43% | 40.39% | 46.87% | 51.79% |
| Normalized Diluted EPS | 27.71% | 2.58% | 29.77% | 43.47% | 44.88% |
| Average Basic Shares Outstanding | 11.05% | 8.93% | 7.31% | 6.88% | 7.57% |
| Average Diluted Shares Outstanding | 11.05% | 8.93% | 7.30% | 6.86% | 7.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |